• Pfizer and BioNTech first to release large trial results
• Expertssay results show vaccines can halt pandemic
• Markets surge on hopes of light at the end of the tunnel 

Nov 9 (Reuters) - Pfizer Inc said on Monday its experimental COVID-19 vaccine was more than 90% effective, a major victory in the fight against a pandemic that has killed more than a million people, battered the world's economy and upended daily life. Pfizer and German partner BioNTech SE are the first drugmakers to release successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns and expect to seek U.S. authorization this month for emergency use of the vaccine. Health experts said Pfizer's results were positive for all COVID-19 vaccines currently in development since they show the shots are going after the right target and are a proof of concept that the disease can be halted with vaccination. 'Today is a great day for science and humanity,' Albert Bourla, Pfizer's chairman and chief executive, said. 'We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.' If Pfizer's vaccine is authorized, the number of doses will initially be limited and many questions remain, including how long the vaccine will provide protection. BioNTech Chief Executive Ugur Sahin told Reuters he was optimistic the immunisation effect of the vaccine would last for a year although that was not certain yet. 'This news made me smile from ear to ear. It is a relief to see such positive results on this vaccine and bodes well for COVID-19 vaccines in general,' said Peter Horby, professor of emerging infectious diseases at the University of Oxford.